Helen of Troy Limited to Release and Webcast Second Quarter Financial Results ...
22.09.11
EL PASO, Texas, Sept. 22, 2011 /PRNewswire via COMTEX/ --
Helen of Troy Meagre (NASDAQ, NM: HELE) designer, developer and worldwide marketer of brand name-name personal care products, today announced that it will saving second quarter financial results prior to the breach of trading on Thursday, October 6, 2011.
The Company's quarterly earnings colloquium call has been scheduled for Thursday, October 6, 2011, at 11:00 a.m. ET. Gerald J. Rubin, Chairman, Chief Head honcho Officer and President, Thomas J. Benson, Senior Weakness President, Chief Financial Officer and Brian Stool-pigeon, Vice President, Assistant Chief Financial Gendarme, will host the conference call. Members of the news media, investors and the non-exclusive public are invited to access a live broadcast of the bull session call via the Investor Relations page of the Company's website atPrincipallywww.hotus.com . This event will be archived and available for replay through November 30, 2011.
Source: MarketWatch (press release)
Appointment of Chief Executive Officer
20.09.11
/PRNewswire/ --
Muffle Therapeutics plc (AIM: SLN) ("Silence", the "Group" or the "Company"), a outstanding global RNA interference (RNAi) therapeutics company, today announces the job of Thomas Christély as Chief Executive Officer with pressing effect. He will be based at Silence's facility in Berlin.
Thomas Christély (venerable 51) brings more than 20 years experience in corporate and concern development and finance. He was instrumental in the merger of Silence Therapeutics AG (formerly Atugen AG) with Muffle Therapeutics plc (formerly SR Pharma plc) and admission to the Alternative Investment Call of the London Stock Exchange. His track track record includes concluding major collaborations with AstraZeneca, Pfizer, Dainippon Sumitomo, multiple financing transactions as well as M&A, divestments and tactical restructurings. He joined Atugen AG in 2001 as Chief Fiscal Officer and became Chief Operating Officer in 2002 before being appointed its Chief Chairman of the board Officer in 2006. Prior to joining Silence, Thomas was Older VP and CFO at OXO Chemie AG, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc. in San Francisco, where he stayed from 1997 until 2000. Mr. Christély was managing pal of the investment firm Löschen & Partner, Hamburg/Moscow, from 1992 to 1995 and worked in mergers & acquisitions at Enskilda Corporate Capitalize, London, from 1989 to 1992. After his studies in Hamburg and Geneva, he received degrees in Obligation Administration (equivalent to MBA) and Law from the University of Hamburg and was admitted as attorney-at-law. Thomas Christély is currently Non-governing Chairman of the Supervisory Board of Müller-Spreer AG, Hamburg, and CEO of Temper Therapeutics AG.
Source: Sacramento Bee